Benjamin Smith

Canada, Western Region

Lead Financial Writer at The Dales Report

Senior Financial Writer @ Skyline Group of Companies. Capital markets professional, commentator & marketer.

Featured in: Favicon

thedalesreport.com Favicon

statnews.com Favicon

einnews.com Favicon

invesbrain.com Favicon

mexicobusinesstoday.com

Articles

Trulieve Sues Florida GOP For Amendment 3 Disinformation Campaign

Oct 3, 2024 | thedalesreport.com | Benjamin Smith

Trulieve Cannabis, Florida’s largest medical cannabis company, is taking off the gloves against purported political interference in the state. Yesterday, the company filed a defamation lawsuit against the Florida Republican Party (GOP) for misinforming voters regarding a proposed constitutional amendment that would permit the legal recreational use of cannabis. A purposeful deception at the highest levels of state government.
Cannabis Talk In Tonight’s Presidential Debate Between Harris and Trump?

Sep 10, 2024 | thedalesreport.com | Benjamin Smith

Democrat Kamala Harris and Republican Donald Trump will face off in a presidential debate on Tuesday night, their first and potentially decisive encounter ahead of the November election. With both candidates polling closely nationwide and in key swing states, the debate could be a turning point in the 2024 campaign. For cannabis investors, the key question is whether the issue will take center stage, especially following Trump’s recent endorsement of Florida’s Amendment 3 ballot initiative.
Trump Endorses Florida’s Amendment 3 to Legalize Recreational Cannabis

Sep 2, 2024 | thedalesreport.com | Benjamin Smith

In one of his most explicit opinions on recreational cannabis to date, former U.S. President Donald Trump signaled that a possible Trump administration in 2025 may be more amenable to the industry than widely perceived. Trump’s comments on Florida’s Amendment 3, which seeks to legalize recreational marijuana in the state.
atai Life Sciences Announces Strategic Investment In Beckley Psytech Limited

Jan 4, 2024 | thedalesreport.com | Benjamin Smith

atai Life Sciences (NASDAQ: ATAI) has made a play to bolster their psychedelics portfolio. The company announced a strategic investment in Beckley Psytech Limited, a private clinical-stage biotechnology firm committed to converting short-duration psychedelics into medicines for neuropsychiatric conditions.
Approval For The Spot Bitcoin ETF Appears On Track, Despite Matrixport Skepticism

Jan 3, 2024 | thedalesreport.com | Benjamin Smith

In response to the recent chatter surrounding the eagerly anticipated Bitcoin spot ETF for the US market, Bloomberg senior analyst Eric Balchunas expressed his perspective, asserting that he has observed only positive indicators leading up to the impending decision. He expressed bewilderment over the assertions made by the Matrixport analyst in a recently published report. Matrix on Target projects a January rejection for Bitcoin Spot ETFs by the SEC, cautioning traders to hedge long exposure.
Ontario Doubles Cannabis Retail Dispensary Capability

Jan 3, 2024 | thedalesreport.com | Benjamin Smith

On January 1, 2024, changes took effect to Ontario Regulation 468/18 that affect licensed retail cannabis operators and their affiliates in the province. Changes to the Cannabis License Act now permit organizations to double the number of stores they operate, raising the cap from 75 to 150. The government asserts that this move is aimed at curbing the illegal cannabis market, aligning with similar regulations in other provinces.
AMA CPT III Codes For Psychedelic-Assisted Therapies Take Effect

Jan 2, 2024 | thedalesreport.com | Benjamin Smith

While psychedelic trials continue to amass promising data on the clinical side, an important event has taken place as it relates to reimbursement. The American Medical Association‘s (AMA) Current Procedural Terminology (CPT) III codes for psychedelic-assisted therapies, as initially unveiled in July 2023, have officially been activated and went into effect January 1, 2024.
atai Life Sciences Announces Positive Data For Orally Administered MDMA Derivative EMP-01

Jan 2, 2024 | thedalesreport.com | Benjamin Smith

atai Life Sciences (NASDAQ: ATAI), the tier-1 biopharmaceutical trialing psychedelic compounds for the treatment of mental health disorders, has unveiled positive findings from its Phase 1 investigation assessing the orally administered EMP-01—a R-enantiomer of MDMA (3,4-methylenedioxy-methamphetamine). An enantiomer is one of two stereoisomers that are mirror images of each other but cannot be superimposed onto one another. Great headline from $ATAI to kick off the first trading day of the year.
TDR’s Top 7 Cannabis Developments For The Week Of December 25

Dec 29, 2023 | thedalesreport.com | Benjamin Smith

Welcome to TDR’s review of the Top 7 Cannabis Developments for the week of December 25. Aside from presenting a synopsis of news events, interviews and closing market prices for publicly-listed companies. 7.
War-Torn Nation Of Ukraine Approves Bill To Legalize Medical Cannabis

Dec 21, 2023 | thedalesreport.com | Benjamin Smith

The Ukraine Parliament took a significant step towards the legalization of medical cannabis on Thursday. The legislative initiative approved a corresponding bill which garnered substantial support with 248 votes in favor and faced opposition from 16 members, according to local media outlets. This legislative advancement followed a previous obstruction by an opposition party, which impeded the bill’s progress through Parliament.